MedTrace Logo

Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis

NCT01065727 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2012-12-03

No results posted yet for this study

Summary

Cost-effectiveness study of 2 disease-modifying therapies (natalizumab versus mitoxantrone followed by immunomodulator) in the management of aggressive remitting multiple sclerosis

Conditions

Interventions

OTHER

mitoxantrone - immunomodulator

mitoxantrone during 6 months and followed by immunomodulator during 2 years and half

OTHER

natalizumab

monthly natalizumab during 3 years

Sponsors & Collaborators

  • Rennes University Hospital

    lead OTHER

Principal Investigators

  • Edan Gilles, MD PhD · Rennes University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2016-02-29
Completion
2019-02-28

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01065727 on ClinicalTrials.gov